Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATRix / IELSG43
DRKS00005503Phase 3Completed
- Sponsor
- Stuttgart Cancer Center
- Start
- Apr 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised trial of rituximab, methotrexate, cytarabine, thiotepa, carmustine and 5 more in primary central nervous system lymphoma (PCNSL) and diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Stuttgart Cancer Center. Started Apr 2014; status: completed.
02
Drugs
rituximabmethotrexatecytarabinethiotepacarmustine
03
Conditions
primary central nervous system lymphoma (PCNSL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on DRKS00005503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00005503.